Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 15, 2009

Molecular Partners Raises Almost $45M to Support Phase II Trials in Ophthalmology

  • Germany-based Molecular Partners raised CHF 46 million (about $44.24 million) in a Series B equity investment round. The company aims to use the new funds to progress its lead VEGF antagonist, MP0112, into Phase II studies in two separate ophthalmology indications. The financing will also be used to support development of its preclinical pipeline of DARPin candidates.

    DARPins are a class of therapeutic proteins that combine the high specificity, selectivity, and safety of mAbs with advantages of small molecules, including high-stability and low-cost production, according to Molecular Partners.

    In May the company reported the early achievement of all milestones in the research phase of its collaboration with Centocor. The alliance is focused on developing DARPin antagonists against two undisclosed inflammatory disease targets. Molecular Partners also has ongoing DARPin collaborations with Roche and Bayer Schering Pharma.

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »